

August 4th, 2020
Eisai Co., Ltd.

Notice of Emergence of Employees Infected with the Novel Coronavirus
at Eisai's Vizag Plant in India

Eisai has ascertained that 6 employees working in active pharmaceutical ingredient (API) manufacturing at its Vizag Plant in India have been infected with the novel coronavirus infection.

On July 31, the infection of one employee was ascertained. As a result of conducting PCR testing on all employees in close contact with the initial infected employee, as of August 2nd 6 employees including the initial infected employee were confirmed positive for the novel coronavirus.

All employees with confirmed infection have been evaluated as asymptomatic and per the direction of medical doctors are in self-quarantine at home. In addition, all employees who have possibly had close contact with the above 6 employees are in self-quarantine. As a means of infection prevention at the Vizag Plant, three zones consisting of API manufacturing, formulation manufacturing, and research/quality/administration have been isolated to prevent contact among employees of the different zones.

Regarding the API manufacturing facility, disinfection has been completed according to guidelines of the government of India, and operations have been temporarily stopped for 3 days from August 3rd. There are no issues with the quality and the stable supply of products or APIs produced in this plant, as there are sufficient stocks of APIs and the formulation manufacturing zone and research /quality/administration zone are operating as usual.

Eisai is taking measures for the prevention of infection including measurement of body temperature upon arriving at work, hand-washing, disinfection, usage of masks, and maintaining social distance. In addition to continuously acting to maintain the safety of all partners and employees as a highest priority, Eisai will proceed with research and development of medicines and the stable supply thereof in order to fulfill its social responsibility as a pharmaceutical company even in emergency circumstances. To learn more about Eisai's response against the novel coronavirus infection, please view the [information](#) posted on our corporate website.